Tricyclo Ring System Having The Seven-membered Hetero Ring A One Of The Cyclos Patents (Class 514/217)
-
Publication number: 20110028453Abstract: Use of a compound that is a serotonin transporter inhibitor, a selective norepinephrine reuptake inhibitor, or a 5-HT1A agonist for alleviating negative symptoms in a schizophrenia patient who carries a defective neuregulin 1 gene.Type: ApplicationFiled: July 27, 2010Publication date: February 3, 2011Inventors: Wen-Mei Fu, Ya-Hsuan Chiang, Hai-Gwo Hwu, Chih-Min Liu
-
Publication number: 20110021502Abstract: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.Type: ApplicationFiled: August 25, 2010Publication date: January 27, 2011Inventor: Roger Michael LANE
-
Publication number: 20110021499Abstract: Urethral suppositories containing a mixed-activity anti-cholinergic drug and methods of use for treatment of over-active bladder are provided. Buffering drugs to pH near their pKas can result in a desired proportion of uncharged drug and can enhance absorption of the agents into urethral tissues.Type: ApplicationFiled: July 22, 2009Publication date: January 27, 2011Inventors: Amie Ellen Franklin, Dennis H. Giesing
-
Patent number: 7872043Abstract: The invention relates to the use of one or several synthetic or natural furan alkyls for cosmetically treating cellulite. Said furan alkyls preferably correspond to formula (I), wherein identical or different R1, R2, R3et R4 are independently of each other a hydrogen atom, a C1-C35alkyl radical, C1-C35 alcenyl radical or a C1-C35 alcynyl radical, preferably C10-C22, wherein said alkyl, alcenyl and alcynyl radicals are substitutable and R1, R2, R3 are preferably a hydrogen atom.Type: GrantFiled: May 27, 2005Date of Patent: January 18, 2011Assignee: Laboratories ExpanscienceInventors: Antoine Piccirilli, Philippe Msika, Nathalie Piccardi
-
Publication number: 20110009351Abstract: The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF) and nephrogenic diabetes insipidus (NDI). The usual approach involves expressing the mutant form of the gene in cells and assaying function in a multiwell format when cells are exposed to libraries of compounds. Although such functional assays are useful, they do not directly test the ability of a compound to correct defective trafficking of the protein. To address this a novel corrector screening assay for CF has been developed in which the appearance of the mutant protein at the cell surface is measured as the assay output. This assay was used to screen more than 3100 compounds. This novel screening approach to protein trafficking diseases is robust and general, and may enable the selection of molecules that can be translated rapidly to a clinical setting.Type: ApplicationFiled: May 9, 2008Publication date: January 13, 2011Inventors: David Y. Thomas, John Hanrahan, Graeme Carlile, Renaud Robert
-
Patent number: 7867999Abstract: Methods for using hydroxyamino- and amino-substituted pyridine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of hydroxyamino- and amino-substituted pyridine analogs, are disclosed herein.Type: GrantFiled: December 19, 2006Date of Patent: January 11, 2011Assignee: Alcon Research, Ltd.Inventors: Hwang-Hsing Chen, Najam A. Sharif, Mark R. Hellberg
-
Patent number: 7858612Abstract: The present invention relates to a method for maintaining the remission of or treating inflammatory bowel diseases, which comprises administering a maintenance therapeutically effective amount or a therapeutically effective amount of 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzoazepine, a prodrug thereof, or a pharmaceutically acceptable salt thereof to a mammal, wherein the prodrug is 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzoazepine. The method according to the present invention is effective in the maintenance therapy and therapy of the inflammatory bowel diseases and has few side effects. Particularly, the method according to the present invention may exhibit strong maintenance therapeutic and therapeutic effects, even on severe cases having resistance to the conventional therapeutics.Type: GrantFiled: December 17, 2008Date of Patent: December 28, 2010Assignee: Meiji Seika Kaisha, Ltd.Inventors: Tomohisa Ninomiya, Takashi Shishikura, Mitsuhiro Uchida, Sho Takahata, Yukari Hoshina, Ken-ichi Kawano
-
Patent number: 7855195Abstract: The present invention relates to methods of treating of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena- . . . ) using compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.Type: GrantFiled: January 6, 2004Date of Patent: December 21, 2010Assignee: PharmaNeuroBoost N.V.Inventor: Erik Buntinx
-
Publication number: 20100317633Abstract: This invention is directed to a hexahydro-cyclooctyl pyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.Type: ApplicationFiled: August 26, 2010Publication date: December 16, 2010Inventors: Mingde Xia, Fina Liotta, Huajun Lu, Meng Pan, Michael P. Wachter, Mark J. Macielag
-
Publication number: 20100311710Abstract: The present invention relates to new cyclobutanemethanamine inhibitors of monoamine reuptake, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 4, 2009Publication date: December 9, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar, Manouchehr M. Shahbaz
-
Publication number: 20100311727Abstract: Therapeutic amine-arylsulfonamide conjugate compounds, of the general formula: wherein R? is [D-W-], hydroxyl, or alkoxyl; R? is independently [D-W?-], hydrogen, alkoxy, alkyl, cycloalkyl, alkenyl, alkynyl or aryl, or R? and R? together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7- or 8-membered ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur; D is independently a therapeutic amine radical comprising at least one nitrogen atom and optionally at least one oxygen atom coupled to W or W? by a nitrogen or oxygen atom; W and W? are a chemical bond or linker; wherein either R? is [D-W-] or at least one R? is [D-W?-], and pharmaceutically acceptable esters, amides, salts or solvates thereof, pharmaceutical compositions containing same, methods for their preparation, and their use in treating psychiatric, neurologic and metabolic disorders are disclosed.Type: ApplicationFiled: June 8, 2010Publication date: December 9, 2010Applicant: ALGEBRA, INC.Inventors: Philip F. MORGAN, James L. KELLEY
-
Publication number: 20100310512Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: May 12, 2010Publication date: December 9, 2010Inventors: Hongyan Guo, Darryl Kato, Thorsten A. Kirschberg, Hongtao Liu, John O. Link, Michael L. Mitchell, Jay P. Parrish, Jianyu Sun, James Taylor, Elizabeth M. Bacon, Eda Canales, Aesop Cho, Choung U. Kim, Jeromy J. Cottell, Manoj C. Desai, Randall L. Halcomb, Michael Graupe, Evan S. Krygowski, Scott E. Lazerwith, Qi Liu, Richard L. Mackman, Hyung-Jun Pyun, Joseph H. Saugier, James D. Trenkle, Winston C. Tse, Randall W. Vivian, Scott D. Schroeder, William J. Watkins, Lianhong Xu
-
Publication number: 20100311701Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: ApplicationFiled: June 2, 2010Publication date: December 9, 2010Applicants: Transform Pharmaceuticals, Inc, University Of South Florida, The Regents of the University Of MichiganInventors: Orn Almarsson, Magali Bourghol Hickey, Matthew Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Publication number: 20100311728Abstract: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.Type: ApplicationFiled: July 23, 2010Publication date: December 9, 2010Inventor: Ashiwel S. Undieh
-
Publication number: 20100305103Abstract: This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or bipolar disorder thereby providing prognostic and diagnostic markers for the disorder. In addition genes are identified whose dysregulation provides markers that allow diagnostic distinction between schizophrenia and bipolar disorder.Type: ApplicationFiled: May 13, 2010Publication date: December 2, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Marquis P. Vawter, Ling Shao
-
Publication number: 20100305095Abstract: The present invention relates to, inter alia, the use of a compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The invention also provides for the use of a compound capable of inhibiting HPPD in an animal in the manufacture of a medicament for use in the treatment of the withdrawal symptoms associated with an addictive drug which causes dopamine dependant associative learning disorders in said animal. In a particular embodiment said HPPD inhibitor is selected from the group consisting of the compound depicted as compound 1; 2; and 3.22.Type: ApplicationFiled: August 18, 2006Publication date: December 2, 2010Inventors: Kim Zachary Travis, John Posner
-
Publication number: 20100297251Abstract: The present invention provides a system for delivery of an enteric coated active agent generally resistant to disintegration in an neutral environment having one or more active agents encapsulated by a polymer coating formed by chemical vapor deposition of one or more monomers on the one or more active agents to form a chemical vapor deposition polymer coating that controls the release of the one or more active agents in the gastrointestinal tract.Type: ApplicationFiled: May 21, 2010Publication date: November 25, 2010Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, AEONCLAD COATINGS, LLCInventors: Richard B. Timmons, Ceren Susut, Donald E. Owens, III, J. Brian Windsor, Rachel Kennedy Khorzad
-
Publication number: 20100298296Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer.Type: ApplicationFiled: November 28, 2008Publication date: November 25, 2010Applicant: Nektar TherapeuticsInventors: Wen Zhang, Xuyuan Gu, Stephanie Allums, Jennifer Riggs-Sauthier
-
Publication number: 20100297181Abstract: The invention provides methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and/or deficits in sensory organ. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, one or more other active ingredients that are useful for treating epilepsy, mental disorders and/or deficits in sensory organ.Type: ApplicationFiled: December 26, 2008Publication date: November 25, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Takahisa Hanada, Shigeki Hibi, Kazuki Miyazaki
-
Publication number: 20100292216Abstract: This invention relates to methods and compositions for treating psychiatric conditions, such as depression.Type: ApplicationFiled: November 16, 2009Publication date: November 18, 2010Applicant: ADAMAS PHARMACEUTICALS, INC.Inventors: Laurence R. Meyerson, Gregory T. Went, Timothy J. Fultz
-
Publication number: 20100292217Abstract: The present invention relates to a method for CNS disorders such as epilepsy and migraine comprising the administration of a therapeutically effective amount of ranolazine.Type: ApplicationFiled: May 13, 2010Publication date: November 18, 2010Applicant: Gilead Palo Alto, Inc.Inventors: Luiz Belardinelli, Alfred George, Kristopher Kahlig, Sridharan Rajamani
-
Publication number: 20100291151Abstract: The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5-HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 21, 2010Publication date: November 18, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100292165Abstract: The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to methods and pharmaceuticals for the treatment of intestinal neoplasia. The invention discloses the surprising finding that inhibitors of Notch pathway activation (for example, ?-secretase inhibitors) are extremely useful in the treatment of intestinal adenoma and/or adenocarcinoma.Type: ApplicationFiled: July 26, 2010Publication date: November 18, 2010Applicant: Hubrecht Laboratorium a corporation of the NetherlandsInventors: Johannes Carolus Clevers, Maria Elisabeth Van Gijn, Johannes Hendrikus Van Es
-
Publication number: 20100285119Abstract: Disclosed herein is an extended release pharmaceutical composition comprising at least two populations of extended release minitablets having a core comprising carbamazepine or its pharmaceutical salts, solvates, hydrates, an extended release polymer(s), wherein the extended release polymer of each population of minitablets is unalike. The process for manufacturing said composition is also disclosed.Type: ApplicationFiled: January 12, 2009Publication date: November 11, 2010Applicant: Jubilant Organosys Ltd.Inventor: Murali Krishna Bhavarisetti
-
Publication number: 20100285139Abstract: A pharmaceutical composition for prophylaxis and/or treatment of infections and/or infectious diseases occurring in cystic fibrosis includes at least one antidepressant; at least one dispersant; and at least one pharmaceutically tolerable carrier material.Type: ApplicationFiled: December 22, 2008Publication date: November 11, 2010Applicant: CYCNAD GMBH & CO., KGInventor: Erich Gulbins
-
Publication number: 20100279991Abstract: This invention is directed to a tetrahydro-cyclopentyl pyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.Type: ApplicationFiled: July 15, 2010Publication date: November 4, 2010Inventors: Fina Liotta, Mingde Xia, Michael P. Wachter, Scott A. Beers
-
Publication number: 20100278920Abstract: Drug delivery of resistance reversal agents by polyacrylate nanoparticles for treatment of drug (e.g. chloroquine) resistant malaria. Also provided are drug delivery by polyacrylate nanoparticles of ciprofloxacin for treatment of anthrax.Type: ApplicationFiled: April 26, 2010Publication date: November 4, 2010Applicant: University of South FloridaInventors: Edward Turos, Ryan Cormier, Dennis E. Kyle
-
Patent number: 7825156Abstract: A benzamide derivative, especially amisulpride, is used to prevent or treat bipolar depression of a patient suffering from bipolar disorder I or bipolar disorder II.Type: GrantFiled: January 11, 2008Date of Patent: November 2, 2010Assignee: CopharmsInventor: Jean-Michel Azorin
-
Publication number: 20100273773Abstract: The present invention is related to novel tricyclic compounds of formula (I) having TRPA1 receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use as pharmacological tools, or as irritant incapacitants, or in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans.Type: ApplicationFiled: December 4, 2008Publication date: October 28, 2010Inventors: Henricus Jacobus Maria Gijsen, Marc Hubert Mercken
-
Publication number: 20100266711Abstract: The present invention relates to new thienobenzodiazepine modulators of D1 receptors, D2 receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 24, 2009Publication date: October 21, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100267695Abstract: [Problems] To provide a compound which is useful as an NMDA receptor antagonist. [Means for Solution] The present inventors have studied a compound having an NMDA receptor antagonistic action, and confirmed that the fused indane compound of the present invention has an excellent NMDA receptor antagonistic action, thereby completed the present invention. The fused indane compound of the present invention has an excellent NMDA receptor antagonistic action and can be used as a prophylactic and/or therapeutic agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, intractable depression, attention deficit hyperactivity disorder, migraines, or the like.Type: ApplicationFiled: November 26, 2008Publication date: October 21, 2010Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi Hayashibe, Shingo Yamasaki, Nobuyuki Shiraishi, Hiroaki Hoshii, Takahiko Tobe
-
Patent number: 7812015Abstract: The invention relates to the use of inhibitors of acid sphingomyelinase and/or of inhibitors of products of the reaction catalyzed by this enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferrably neutralizing antibodies and/or antidepressants, especially tricyclic and/or tetracyclic antidepressants, are used as inhibitors.Type: GrantFiled: August 21, 2003Date of Patent: October 12, 2010Inventor: Erich Gulbins
-
Publication number: 20100256116Abstract: A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.Type: ApplicationFiled: July 28, 2009Publication date: October 7, 2010Inventors: Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinov, Tatiana D. Sotnikova, Ranga R. Krishnan, David A. Schwartz, Redford B. Williams, Lauranell Burch
-
Patent number: 7803786Abstract: The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.Type: GrantFiled: June 16, 2005Date of Patent: September 28, 2010Assignees: Transform Pharmaceuticals, Inc., University of South FloridaInventors: Jennifer McMahon, Matthew Peterson, Michael J. Zaworotko, Tanise Shattock, Magali Bourghol Hickey
-
Publication number: 20100234349Abstract: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.Type: ApplicationFiled: September 4, 2007Publication date: September 16, 2010Inventors: Gunnar M. Olsen, Dan Peters, Bjarne H. Dahl, Jeppe Kejser Christensen, Steven Charles Loechel, Daniel B. Timmermann
-
Publication number: 20100234331Abstract: This invention is directed to a hexahydro-cyclooctyl pyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.Type: ApplicationFiled: May 24, 2010Publication date: September 16, 2010Inventors: Mingde Xie, Fina Liotta, Huajun Lu, Meng Pan, Michael P. Wachter
-
Publication number: 20100222327Abstract: The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.Type: ApplicationFiled: August 4, 2009Publication date: September 2, 2010Inventors: José Luis de Almeida, PatrÃcio Manuel Vieira Araújo Soares Da Silva
-
Publication number: 20100222283Abstract: Methods are provided for treating and preventing renal disease in a subject by administering a gamma secretase inhibitor or a Notch pathway inhibitor to the subject.Type: ApplicationFiled: September 4, 2008Publication date: September 2, 2010Inventors: Katalin Susztak, Bernhard Bielesz, Thiruvur G. Niranjan
-
Publication number: 20100216776Abstract: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon activation of the S100 protein, where the fluorescent dye has decreased fluorescence when exposed to the aqueous solution than when protected from exposure to the aqueous solution. Also provided are methods of treating a subject having metastatic cancer.Type: ApplicationFiled: August 10, 2006Publication date: August 26, 2010Inventors: Anne Reba Bresnick, Sarah Claire Garrett
-
Publication number: 20100215774Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 8, 2008Publication date: August 26, 2010Inventor: Todd Maibach
-
Patent number: 7781425Abstract: A guanidine compound having a biaryl skeleton represented by the following formula (1), which is useful as a catalyst for various asymmetric reactions.Type: GrantFiled: February 9, 2005Date of Patent: August 24, 2010Assignee: Takasago International CoporationInventors: Masahiro Terada, Hitoshi Ube, Shigeko Yokoyama, Hideo Shimizu
-
Publication number: 20100204207Abstract: Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.Type: ApplicationFiled: April 20, 2010Publication date: August 12, 2010Inventors: Xinchao Chen, Christopher Lawrence Cioffi, Sean Richard Dinn, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Saravanan Parthasarathy, Xiaodong Wang
-
Publication number: 20100196466Abstract: A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided.Type: ApplicationFiled: January 29, 2010Publication date: August 5, 2010Applicant: Capricorn Pharma Inc.Inventor: S. Rao CHERUKURI
-
Publication number: 20100197663Abstract: Chronic pain is treated with a combination of a standard dose of a non-narcotic analgesic and a low dose of a tricyclic antidepressant compound. The invention is effective in the treatment of chronic pain associate with neuropathic or fibromuscular disorders, where such pain has been unresponsive to non-narcotic analgesics alone.Type: ApplicationFiled: April 12, 2010Publication date: August 5, 2010Applicant: RODLEN LABORATORIES, INC.Inventor: Joel E. Bernstein
-
Publication number: 20100197661Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.Type: ApplicationFiled: March 23, 2010Publication date: August 5, 2010Inventors: Gideon Dreyfuss, Jin Wang
-
Publication number: 20100190705Abstract: Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell. Also provided are compounds useful for the treatment of Alexander disease in subjects at risk of or diagnosed with Alexander disease and methods for the identification of such compounds.Type: ApplicationFiled: October 26, 2009Publication date: July 29, 2010Inventors: Albee Messing, Woosung Cho, Jon Scott Thorson, Randal D. Goff
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Patent number: 7763612Abstract: Therapeutic amine-arylsulfonamide conjugate compounds, of the general formula: wherein R? is [D-W-], hydroxyl, or alkoxyl; R? is independently [D-W?-], hydrogen, alkoxy, alkyl, cycloalkyl, alkenyl, alkynyl or aryl, or R? and R? together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7- or 8-membered ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur; D is independently a therapeutic amine radical comprising at least one nitrogen atom and optionally at least one oxygen atom coupled to W or W? by a nitrogen or oxygen atom; W and W? are a chemical bond or linker; wherein either R? is [D-W-] or at least one R? is [D-W?-], and pharmaceutically acceptable esters, amides, salts or solvates thereof, pharmaceutical compositions containing same, methods for their preparation, and their use in treating psychiatric, neurologic and metabolic disorders are disclosed.Type: GrantFiled: January 3, 2007Date of Patent: July 27, 2010Assignee: Algebra, Inc.Inventors: Philip F. Morgan, James L. Kelley
-
Patent number: 7763603Abstract: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.Type: GrantFiled: August 9, 2007Date of Patent: July 27, 2010Inventors: Kimberly R. Tyeryar, Ashiwel S. Undie
-
Publication number: 20100184743Abstract: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.Type: ApplicationFiled: February 18, 2010Publication date: July 22, 2010Inventor: Roger Michael Lane